Elacestrant, also known as Orserdu, is an estrogen receptor antagonist used to treat advanced or metastatic breast lesions. It is indicated for postmenopausal women or adult men, especially those who are ER-positive, HER2-negative, and carry ESR1 mutations. Elacestrant helps control the growth and spread of lesions by inhibiting the activity of estrogen receptors.
Is Orserdu/Elacestrant used to treat advanced or metastatic breast disease?
Elacestrant is a novel estrogen receptor antagonist for the treatment of ER-positive, HER2-negative advanced or metastatic breast lesions harboring ESR1 mutations. It provides patients with a new treatment option by blocking the activity of estrogen receptors and inhibiting the growth and spread of diseased cells.
Mechanism of action of Elacestrant
Elacestrant inhibits the growth and spread of lesions by selectively inhibiting estrogen receptors (ERα) and blocking the stimulating effect of estrogen on diseased cells. This mechanism of action allows it to be highly effective in the treatment of ER-positive breast lesions, especially in patients with ESR1 mutations.
Indications for Elacestrant
Elacestrant is indicated for postmenopausal women or adult men with ER-positive, HER2-negative advanced or metastatic breast lesions with ESR1 mutations. It is commonly used in patients whose disease has progressed after at least one form of endocrine therapy to help prolong progression-free survival.
The therapeutic effect of Elacestrant is significant, but patients need to be aware of its possible side effects and related precautions when using it, and we will introduce the dosage of Elacestrant.
What is the dosage of Elacestrant?
The recommended dose of Elacestrant is 345 mg orally once daily with food until disease progression or unacceptable toxicity. Patients should swallow the tablets whole while taking them, avoiding chewing, crushing, or breaking the tablets.
How to take Elacestrant?
Elacestrant should be given 345 mg orally with food once daily. Taking it with food can reduce adverse effects such as nausea and vomiting. If a dose is missed for more than 6 hours or vomiting occurs, the dose should be skipped and the next dose taken at the regular time of the next day.
Dose adjustments
For patients with moderate hepatic impairment (Child-Pugh class B), it is recommended to reduce the dose of Elacestrant to 258 mg once daily. Elacestrant should be avoided in patients with severe hepatic impairment (Child-Pugh class C). Patients with mild hepatic impairment (Child-Pugh class A) do not need to adjust the dose.
The dosing and dosage of Elacestrant need to be adjusted according to the specific situation of the patient, especially in patients with hepatic impairment. Next, we will introduce the side effects of Elacestrant and what to look out for.
What are the side effects and precautions of Elacestrant?
Patients should regularly monitor lipids and liver function during use to prevent possible serious adverse reactions.
Common side effects
Common side effects of Elacestrant include musculoskeletal pain, nausea, elevated cholesterol, fatigue, vomiting, etc. Patients should monitor lipids and liver function regularly during the medication, and adjust the dose or suspend the medication according to the doctor's advice if necessary.
Precautions
Elacestrant may cause dyslipidemia, patients should regularly monitor lipids during the drug, Elacestrant is embryo-fetal toxic, and pregnant women and women of reproductive potential should use effective contraception during use. Breastfeeding should be avoided during use.
Elacestrant is a prescription drug, and patients should strictly follow the doctor's instructions when using it and have regular rechecks to prevent possible serious adverse reactions.
